Samsung watches can predict fainting episodes but caveats remain

At a glance:

• Galaxy Watch 6 can predict vasovagal syncope up to five minutes before it happens
• Study of 132 patients showed 84.6% overall accuracy, 90% sensitivity and 64% specificity
• Real‑world validation is still needed; false‑positive alerts could be a major issue

Samsung touts early‑warning capability for fainting

Samsung announced that its Galaxy Watch 6 may be able to warn wearers of an impending vasovagal syncope (VVS) episode. The claim is backed by a joint clinical study with Chung‑Ang University Gwangmyeong Hospital in South Korea, which used the watch’s photoplethysmography (PPG) sensor to collect heart‑rate‑variability data during head‑up tilt testing. An artificial‑intelligence algorithm then processed the data and attempted to predict a fainting event before it occurred.

The researchers described the work as the "world's first study" to demonstrate a commercial smartwatch’s potential for early syncope detection. Results were published in the European Heart Journal – Digital Health, giving the effort a peer‑reviewed platform and a clear scientific record.

Why early warnings matter

Vasovagal syncope is one of the most common forms of fainting, affecting up to 40 % of people at some point in their lives, according to Prof. Junhwan Cho of Chung‑Ang University Gwangmyeong Hospital. While the loss of consciousness itself is rarely fatal, the sudden fall that follows can cause concussions, fractures or other injuries. Dr. Sam Setareh of the Beverly Hills Cardiovascular and Longevity Institute emphasized that even a few minutes of advance notice could let a person sit, lie down, hydrate or call for help, potentially averting serious secondary harm.

Study details and performance metrics

The study enrolled 132 participants who were undergoing a deliberately provocative tilt‑table test designed to induce syncope. Using the watch‑derived heart‑rate‑variability data, the AI model predicted fainting episodes up to five minutes in advance with an overall accuracy of 84.6 %. Sensitivity – the ability to correctly flag true fainting events – reached 90 %, while specificity – the ability to avoid false alerts – was 64 %.

These numbers indicate that while the system catches most real events, a substantial proportion of alerts could be false positives. In a controlled laboratory environment that rate might be tolerable, but in everyday life it could translate into a flood of unnecessary warnings.

Concerns over false positives and real‑world noise

Dr. Brett A. Sealove, chair of cardiology at Hackensack Meridian Jersey Shore University Medical Center, warned that the 64 % specificity is a major limitation. In the wild, where millions of users go about daily activities, motion artifacts, hydration status, posture, medication, alcohol, anxiety and other variables could degrade signal quality and inflate false‑alarm rates.

Sealove also noted that the study population was highly selected – all participants had a known history of neurally mediated syncope and were subjected to a laboratory protocol that deliberately provoked fainting. The algorithm’s performance in people without prior syncope, or in everyday settings such as cooking, walking on a crowded platform, or exercising, remains unknown.

Risk of false reassurance and medical oversight

Dr. Rab Nawaz Khan, a board‑certified neurologist at the San Francisco‑based startup MyMigraineTeam, cautioned that a lack of an alert should not be interpreted as safety. Users with chest pain, palpitations, seizure‑like activity or other concerning symptoms still need professional evaluation, regardless of smartwatch feedback.

Both Khan and Setareh agree that wearables are emerging as valuable preventive health tools, but they are not replacements for clinical diagnosis. The most realistic use case today is an additional warning layer for individuals already diagnosed with recurrent VVS, giving them a brief window to take protective actions.

The road ahead: larger, real‑world studies

Experts stress that larger, multicenter trials are required to assess the algorithm across diverse ages, skin tones, activity levels and health conditions. Critical questions include whether the feature works when the watch is worn loosely, during intense motion, or under varying environmental conditions, and whether alerts actually reduce injury rates.

Sealove called the Samsung study a "meaningful milestone" because it used a commercial smartwatch rather than a medical‑grade device, but he reiterated that most wearables are not yet ready for diagnostic or treatment recommendations. Until broader validation is achieved, Samsung has not announced a rollout timeline for a faint‑warning feature to the general public.

What this means for consumers

For now, owners of the Galaxy Watch 6 (or newer models) should view the fainting‑prediction capability as an experimental feature that may help those with a known history of VVS. The technology showcases how AI‑driven analytics can extract subtle physiological patterns from everyday sensors, but it also highlights the challenges of translating lab‑grade performance into reliable consumer health tools.

Future updates from Samsung, possibly incorporating larger datasets and refined algorithms, could bring the promise of real‑time fainting alerts closer to everyday reality. Until then, users should continue to rely on standard medical advice and treat smartwatch alerts as supplementary information rather than definitive warnings.